Deutsche Bank Maintains Buy on Spyre Therapeutics, Raises Price Target to $88

Benzinga Newsdesk www.benzinga.com Positive 82.8%

Neg 0% Neu 0% Pos 82.8%

Deutsche Bank analyst David Hoang maintains Spyre Therapeutics (NASDAQ:SYRE) with a Buy and raises the price target from $55 to $88.